anakinra
AssetAlso Kineret®, r-metHuIL-1ra, Anakinra (Kineret®), Anakinra 100 mg
Recombinant interleukin-1 receptor antagonist blocking the biological activity of IL-1alpha and IL-1beta
- Stage
- Approved
- Modality
- Protein or enzyme
- Target
- Inflammation
- 15
- Indications
- 122
- Trials
- 2
- Developers
Indications
15Arthritis
Approved, ema.europa.eu, 7 Oct 2026
Arthritis, Rheumatoid
Approved, accessdata.fda.gov, 7 Oct 2026
COVID-19
Approved, ema.europa.eu, 7 Oct 2026
12 more
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials122
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals7
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 9 sources